Tharimmune, Inc.

The momentum for this stock is not very good. Tharimmune, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Tharimmune, Inc..

News

Tharimmune, Inc. (NASDAQ:THAR) Short Interest Down 35.7% in July

Ticker Report Tharimmune, Inc. (NASDAQ:THAR - Get Free Report) was the recipient of a significant decline in short interest in July. As of July 31st, there was short interest totalling 18,900 shares, a decline of...\n more…

THAR Stock Earnings: Tharimmune Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nTharimmune just reported results for the second quarter of 2024.\nThe post THAR Stock Earnings: Tharimmune Reported Results for Q2 2024...\n more…

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Accesswire BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ('Tharimmune' or the 'Company'), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates...\n more…

Tharimmune appoints David Clarke as strategic advisor

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Accesswire BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ('Tharimmune' or the 'Company'), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates...\n more…